Tình trạng hiện tại và ý nghĩa của microRNAs trong chẩn đoán và điều trị ung thư buồng trứng

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012,62(1):10–29. 10.3322/caac.20138

Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog TJ: Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009,115(18):4118–4126. 10.1002/cncr.24461

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007,14(5):195–208. 10.3747/co.2007.148

Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Moriya T, et al.: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006,94(10):1369–1374. 10.1038/sj.bjc.6603116

du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, et al.: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003,95(17):1320–1329. 10.1093/jnci/djg036

Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004,164(5):1511–1518. 10.1016/S0002-9440(10)63708-X

Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, et al.: Ovarian Cancer, Version 3.2012. J Natl Compr Canc Netw 2012,10(11):1339–1349.

Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P: Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree. Gynecol Oncol 2012. Sep 21 (Epub ahead of print).

Gonzalez-Martin A, Chiva L: Emerging Concerns When Evidence-Based Medicine Is Translated into Real Life: The Case of Neoadjuvant Chemotherapy in Ovarian Cancer. Curr Oncol Rep 2012. Oct 9 (epub ahead of print).

Cannistra SA: Cancer of the ovary. N Engl J Med 2004,351(24):2519–2529. 10.1056/NEJMra041842

Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007,33(1):9–23. 10.1016/j.ctrv.2006.09.006

Fraser M, Bai T, Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008,122(3):534–546. 10.1002/ijc.23086

Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL: Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007,67(7):3036–3042. 10.1158/0008-5472.CAN-06-3755

Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006,12(17):5055–5063. 10.1158/1078-0432.CCR-06-0861

Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006,23(6):1324–1331. 10.1007/s11095-006-0136-6

Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, Scambia G: Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 2007,7(8):704–712. 10.2174/156800907783220453

Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004,116(2):281–297. 10.1016/S0092-8674(04)00045-5

Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009,55(4):623–631. 10.1373/clinchem.2008.112805

Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008,111(3):478–486. 10.1016/j.ygyno.2008.08.017

Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, et al.: Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 2012. Aug 13, (Epub ahead of print).

Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y, Ding Y, Zhang Y, Yang BB, Peng C: MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 2011,124(Pt 3):359–368.

Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993,75(5):843–854. 10.1016/0092-8674(93)90529-Y

Wheeler BM, Heimberg AM, Moy VN, Sperling EA, Holstein TW, Heber S, Peterson KJ: The deep evolution of metazoan microRNAs. Evol Dev 2009,11(1):50–68. 10.1111/j.1525-142X.2008.00302.x

Ambros V: The functions of animal microRNAs. Nature 2004,431(7006):350–355. 10.1038/nature02871

Cai X, Hagedorn CH, Cullen BR: Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004,10(12):1957–1966. 10.1261/rna.7135204

Kim YK, Kim VN: Processing of intronic microRNAs. EMBO J 2007,26(3):775–783. 10.1038/sj.emboj.7601512

Pratt AJ, MacRae IJ: The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem 2009,284(27):17897–17901. 10.1074/jbc.R900012200

Fabian MR, Mathonnet G, Sundermeier T, Mathys H, Zipprich JT, Svitkin YV, Rivas F, Jinek M, Wohlschlegel J, Doudna JA, et al.: Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell 2009,35(6):868–880. 10.1016/j.molcel.2009.08.004

Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007,27(1):91–105. 10.1016/j.molcel.2007.06.017

Gu S, Jin L, Zhang F, Sarnow P, Kay MA: Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol 2009,16(2):144–150. 10.1038/nsmb.1552

Vasudevan S, Tong Y, Steitz JA: Cell-cycle control of microRNA-mediated translation regulation. Cell Cycle 2008,7(11):1545–1549. 10.4161/cc.7.11.6018

Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of mammalian microRNA targets. Cell 2003,115(7):787–798. 10.1016/S0092-8674(03)01018-3

Flynt AS, Lai EC: Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008,9(11):831–842. 10.1038/nrg2455

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al.: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002,99(24):15524–15529. 10.1073/pnas.242606799

Zhang W, Dahlberg JE, Tam W: MicroRNAs in tumorigenesis: a primer. Am J Pathol 2007,171(3):728–738. 10.2353/ajpath.2007.070070

Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al.: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005,353(17):1793–1801. 10.1056/NEJMoa050995

Calin GA, Croce CM: Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007,117(8):2059–2066. 10.1172/JCI32577

Tagawa H, Seto M: A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 2005,19(11):2013–2016. 10.1038/sj.leu.2403942

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al.: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004,101(9):2999–3004. 10.1073/pnas.0307323101

Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, et al.: miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008, 7: 255–264. 10.4161/cbt.7.2.5297

Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006,9(6):435–443. 10.1016/j.ccr.2006.04.020

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al.: MicroRNA signatures in human ovarian cancer. Cancer Res 2007,67(18):8699–8707. 10.1158/0008-5472.CAN-07-1936

Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007,39(5):673–677. 10.1038/ng2003

He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al.: A microRNA component of the p53 tumour suppressor network. Nature 2007,447(7148):1130–1134. 10.1038/nature05939

Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al.: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008,105(19):7004–7009. 10.1073/pnas.0801615105

Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, et al.: microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006,103(24):9136–9141. 10.1073/pnas.0508889103

Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008,14(9):2690–2695. 10.1158/1078-0432.CCR-07-1731

Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, Becker KG, Morin PJ, Wood W: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008,3(6):e2436. 10.1371/journal.pone.0002436

Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009,4(4):e5311. 10.1371/journal.pone.0005311

Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB: MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 2009,4(10):e7314. 10.1371/journal.pone.0007314

Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al.: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008,68(2):425–433. 10.1158/0008-5472.CAN-07-2488

Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008,283(22):14910–14914. 10.1074/jbc.C800074200

Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005,17(5):548–558. 10.1016/j.ceb.2005.08.001

Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008,22(7):894–907. 10.1101/gad.1640608

Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008,10(5):593–601. 10.1038/ncb1722

Gregory PA, Bracken CP, Bert AG, Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008,7(20):3112–3118. 10.4161/cc.7.20.6851

Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH: miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009,27(8):1712–1721. 10.1002/stem.101

Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, Oka K, Konishi I: Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 2004,35(12):1469–1476. 10.1016/j.humpath.2004.09.014

Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, et al.: The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011,18(1):85–95.

Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, et al.: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003,22(23):3548–3553. 10.1038/sj.onc.1206419

Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005,4(12):2001–2007. 10.1158/1535-7163.MCT-05-0244

Seve P, Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008,9(2):168–175. 10.1016/S1470-2045(08)70029-9

Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, et al.: Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009,20(8):1414–1419. 10.1093/annonc/mdp002

Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C: Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006,12(9):2774–2779. 10.1158/1078-0432.CCR-05-2715

Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997,100(5):1282–1293. 10.1172/JCI119642

Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, et al.: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005,11(1):298–305.

Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, Kikkawa F: Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 2008,27(2):207–212.

Roush S, Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 2008,18(10):505–516. 10.1016/j.tcb.2008.07.007

Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, et al.: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000,408(6808):86–89. 10.1038/35040556

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al.: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004,64(11):3753–3756. 10.1158/0008-5472.CAN-04-0637

Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, et al.: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008,68(24):10307–10314. 10.1158/0008-5472.CAN-08-1954

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell 2005,120(5):635–647. 10.1016/j.cell.2005.01.014

Bussing I, Slack FJ, Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008,14(9):400–409. 10.1016/j.molmed.2008.07.001

Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al.: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007,67(16):7713–7722. 10.1158/0008-5472.CAN-07-1083

Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008,18(5):549–557. 10.1038/cr.2008.45

Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L: Genomic DNA Copy-Number Alterations of the let-7 Family in Human Cancers. PLoS One 2012,7(9):e44399. 10.1371/journal.pone.0044399

Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ: Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 2010,27(2):406–415. 10.1007/s12032-009-9225-9

Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et al.: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008,7(1):1–9. 10.1158/1535-7163.MCT-07-0573

Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ: MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007,67(23):11111–11116. 10.1158/0008-5472.CAN-07-2858

Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME: Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012,130(8):1787–1797. 10.1002/ijc.26190

Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D: MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol 2011,122(2):366–371. 10.1016/j.ygyno.2011.04.033

Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, et al.: Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010,16(4):1119–1128. 10.1158/1078-0432.CCR-09-2642

Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, et al.: A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010,24(2):447–463. 10.1210/me.2009-0295

Peng DX, Luo M, Qiu LW, He YL, Wang XF: Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 2012,27(4):1238–1244.

Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, et al.: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009,15(17):5404–5413. 10.1158/1078-0432.CCR-09-0365

Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, et al.: Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 2010,70(5):1906–1915. 10.1158/0008-5472.CAN-09-3875

Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al.: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010,11(2):136–146. 10.1016/S1470-2045(09)70343-2

Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pitta C, et al.: microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011,30(10):1990–2007. 10.1038/emboj.2011.102

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006,103(7):2257–2261. 10.1073/pnas.0510565103

Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, et al.: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007,8(10):R214. 10.1186/gb-2007-8-10-r214

Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY, Sun BC, et al.: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol 2011,43(4):632–641. 10.1016/j.biocel.2011.01.002

Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001,98(20):10983–10985. 10.1073/pnas.211430998

Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G: TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010,29(24):3545–3553. 10.1038/onc.2010.111

Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA: TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 1999,75(4):566–577. 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0

Lee MS, Lowe G, Flanagan S, Kuchler K, Glackin CA: Human Dermo-1 has attributes similar to twist in early bone development. Bone 2000,27(5):591–602. 10.1016/S8756-3282(00)00380-X

Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, et al.: A twist code determines the onset of osteoblast differentiation. Dev Cell 2004,6(3):423–435. 10.1016/S1534-5807(04)00058-9

Ota MS, Loebel DA, O'Rourke MP, Wong N, Tsoi B, Tam PP: Twist is required for patterning the cranial nerves and maintaining the viability of mesodermal cells. Dev Dyn 2004,230(2):216–228. 10.1002/dvdy.20047

Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, et al.: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008,105(40):15535–15540. 10.1073/pnas.0808266105

Xu G, Zhong Y, Munir S, Yang BB, Tsang BK, Peng C: Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J Clin Endocrinol Metab 2004,89(11):5523–5534. 10.1210/jc.2004-0893

Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM: Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009,100(7):1234–1242. 10.1111/j.1349-7006.2009.01164.x

Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW, et al.: MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 2011,30(7):806–821. 10.1038/onc.2010.465

Fu X, Tian J, Zhang L, Chen Y, Hao Q: Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012,586(9):1279–1286. 10.1016/j.febslet.2012.03.006

Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004,23(34):5853–5857. 10.1038/sj.onc.1207721

Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene 2007,26(19):2799–2803. 10.1038/sj.onc.1210083

Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007,72(5–6):397–402.

Lou Y, Yang X, Wang F, Cui Z, Huang Y: MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med 2010,26(6):819–827.

Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, Tsichlis PN: Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 2011,71(13):4720–4731. 10.1158/0008-5472.CAN-11-0365

Li J, Liang S, Yu H, Zhang J, Ma D, Lu X: An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol 2010,119(3):543–548. 10.1016/j.ygyno.2010.08.034

Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, An HJ: Deregulation of miR-519a, 153, and 485–5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010,57(5):734–743. 10.1111/j.1365-2559.2010.03686.x

Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H: Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007,67(21):10117–10122. 10.1158/0008-5472.CAN-07-2544

Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009,114(3):457–464. 10.1016/j.ygyno.2009.05.022

Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008,110(1):13–21. 10.1016/j.ygyno.2008.04.033

Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME: Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007,104(27):11400–11405. 10.1073/pnas.0704372104

Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010,9(10):775–789. 10.1038/nrd3179

Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z, Yang B: A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 2009,37(3):e24. 10.1093/nar/gkn1053

Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, et al.: Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010,29(11):1580–1587. 10.1038/onc.2009.445

Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ: Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011,19(6):1116–1122. 10.1038/mt.2011.48

Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A: Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011,10(8):1470–1480. 10.1158/1535-7163.MCT-11-0152

Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K: Modulation of microRNA processing by p53. Nature 2009,460(7254):529–533. 10.1038/nature08199

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al.: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011,17(2):211–215. 10.1038/nm.2284

Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, et al.: Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A 2011,108(11):4394–4399. 10.1073/pnas.1014720108

Shan G, Li Y, Zhang J, Li W, Szulwach KE, Duan R, Faghihi MA, Khalil AM, Lu L, Paroo Z, et al.: A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008,26(8):933–940. 10.1038/nbt.1481

Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H: ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 2011,71(9):3410–3421. 10.1158/0008-5472.CAN-10-3340

Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE: Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 2010,31(12):2049–2057. 10.1093/carcin/bgq192

Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, et al.: Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010,5(5):e10630. 10.1371/journal.pone.0010630